Pemvidutide
Fat LossInvestigational GLP-1/glucagon agonistEmerging
Altimmune GLP-1/glucagon dual agonist in development for obesity and MASH. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 2538014-94-5
- Molecular Weight (MW)
- ≈4094 g/mol
- Half-life
- ~110 hours (EuPort™ albumin-binding domain; weekly dosing)
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- 8/23/2026
- Targets
- GLP-1 receptorGlucagon receptor
Overview
Altimmune GLP-1/glucagon dual agonist in development for obesity and MASH. Not FDA-approved.
Protocol
- Dosage Range
- Investigational - dosage under evaluation in clinical trials
- Frequency
- Weekly
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Investigational - not yet established
Science
Mechanism of Action
Dual incretin/glucagon agonism intended to reduce energy intake and increase hepatic fat oxidation versus GLP-1 alone.
Targets
GLP-1 receptorGlucagon receptor
Studies
- Pemvidutide obesity/MASH development— Journal/year not available
Benefits
Obesity and MASH research candidate
Potential Side Effects
- Nausea
- Vomiting
- Heart-rate increase possible
References
- Pemvidutide literatureExternal link · Year —